The estimated Net Worth of Elizabeth Kwo is at least $664 Thousand dollars as of 15 March 2022. Elizabeth Kwo owns over 18,000 units of Flexion Therapeutics Inc stock worth over $663,527 and over the last 4 years he sold FLXN stock worth over $0. In addition, he makes $0 as Director at Flexion Therapeutics Inc.
Elizabeth has made over 1 trades of the Flexion Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 18,000 units of FLXN stock worth $9,540 on 15 March 2022.
The largest trade he's ever made was buying 18,000 units of Flexion Therapeutics Inc stock on 15 March 2022 worth over $9,540. On average, Elizabeth trades about 2,571 units every 0 days since 2020. As of 15 March 2022 he still owns at least 72,201 units of Flexion Therapeutics Inc stock.
You can see the complete history of Elizabeth Kwo stock trades at the bottom of the page.
Dr. Elizabeth Kwo M.D. serves as Director of the Company. Dr. Kwo has more than 15 years of experience specializing in healthcare technology product development and commercialization, marketing and sales, strategic partnerships, and post-merger integration. As Staff Vice President of Clinical Data Analytics at Anthem, she is responsible for creating an improved automated patient and provider experience to drive down cost of care. Prior to Anthem, Dr. Kwo co-founded and served as the CEO of InfiniteMD, a telemedicine company connecting patients with physicians for second opinions. She previously worked at Medtronic, American Well and she also founded multiple venture-backed companies in educational technology, digital healthcare and healthcare supplies. Dr. Kwo earned a BA in Human Biology from Stanford University and her MD from Harvard Medical School. She holds an MBA from Harvard Business School and an MPH from Harvard TH Chan School of Public Health. She completed her residency in Preventive Care at Harvard Preventive Care and is Board Certified in Preventive Care and Occupational Medicine.
Elizabeth's mailing address filed with the SEC is C/O ASENSUS SURGICAL, INC., 1 TW ALEXANDER DRIVE, SUITE 160, DURHAM, NC, 27703.
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon, and Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: